


4D Path partners with Daiichi Sankyo to advance AI-driven ADC programme

April 15, 2026 | News

Collaboration to leverage Q-Plasia OncoReader™ (QPOR™) on routine H&E slides



4D Path, a US-based company dedicated to personalising cancer care through a novel, physics-informed approach to predicting tumor response to therapy, has announced a collaboration with Japan's Daiichi Sankyo to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development programme.

ADCs are among the most promising therapeutic classes in oncology, yet there remains a significant unmet need for scalable biomarkers that predict which patients are most likely to benefit from increasingly complex regimens and combination therapies. This collaboration brings together 4D Path's ability to compute biologically grounded, physics-informed treatment predictive biomarkers from routine pathology specimens with the ADC innovation leadership of Daiichi Sankyo.

Under the collaboration, 4D Path will apply its proprietary Q-Plasia OncoReader™ (QPOR™) platform to standard Hematoxylin and Eosin (H&E)-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics.

These biomarkers will be evaluated for their ability to identify patients most likely to benefit from the select ADC, helping enable more precise, non-invasive, and cost-effective patient selection, potentially improving response rates and accelerating clinical trials.

The collaboration is expected to also generate functional mechanistic insights into tumor-specific patterns of response and resistance—helping illuminate how biological context may interact with ADC designs. By transforming routine pathology images into actionable, physics-informed collective tumour state variables, the agreement aims to enrich translational understanding while supporting more personalised and effective treatment strategies.